Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
Kadoglou
N P E
NP
First Department of Internal Medicine, Hippokratio General Hospital of Thessaloniki, Greece. nikoskad@yahoo.com
Kapelouzou
A
A
Tsanikidis
H
H
Vitta
I
I
Liapis
C D
CD
Sailer
N
N
D052242:Adiponectin / Q000097:blood; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007333:Insulin Resistance / Q000502:physiology; D015850:Interleukin-6 / Q000097:blood*; D008055:Lipids / Q000097:blood; D008297:Male; D008687:Metformin / Q000008:administration & dosage* / Q000494:pharmacology; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D000077154:Rosiglitazone; D015843:Serpins / Q000097:blood*; D045162:Thiazolidinediones / Q000008:administration & dosage* / Q000494:pharmacology
C499918:ADIPOQ protein, human; D052242:Adiponectin; D001786:Blood Glucose; D004338:Drug Combinations; D007004:Hypoglycemic Agents; C508600:IL6 protein, human; D015850:Interleukin-6; D008055:Lipids; C507339:SERPINA12 protein, human; D015843:Serpins; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D008687:Metformin